Seer Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
124
- Stock Symbol
-
SEER
- Share Price
-
$1.39
- (As of Thursday Closing)
Seer General Information
Description
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
Contact Information
Website
www.seer.bioCorporate Office
- 3800 Bridge Parkway
- Suite 102
- Redwood City, CA 94065
- United States
Corporate Office
- 3800 Bridge Parkway
- Suite 102
- Redwood City, CA 94065
- United States
Seer Stock Performance
As of 19-Nov-2026, Seer’s stock price is $1.39. Its current market cap is $82.9M with 55.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.39 | $1.44 | $1.36 - $2.38 | $82.9M | 55.8M | 216K | -$1.14 |
Seer Financials Summary
As of 30-Sep-2026, Seer has a trailing 12-month revenue of $13.6M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,996 | (64,677) | (84,888) | (178,618) |
| Revenue | 13,618 | 16,119 | 13,947 | 15,182 |
| EBITDA | (66,286) | (78,817) | (96,991) | (98,441) |
| Net Income | (63,468) | (73,600) | (86,599) | (86,277) |
| Total Assets | 241,799 | 296,083 | 366,597 | 436,269 |
| Total Debt | 21,742 | 23,652 | 25,964 | 28,259 |
Seer Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Seer Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Seer Comparisons
Industry
Financing
Details
Seer Competitors (7)
One of Seer’s 7 competitors is Nautilus Biotechnology, a Formerly VC-backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nautilus Biotechnology | Formerly VC-backed | Seattle, WA | ||||
| Quanterix | Formerly PE-Backed | Billerica, MA | ||||
| Agilent Technologies | Formerly PE-Backed | Santa Clara, CA | ||||
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Thermo Fisher Scientific | Formerly PE-Backed | Waltham, MA |
Seer Patents
Seer Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026170078-A1 | Methods and systems for high-throughput proteomics discovery | Pending | 06-Feb-2025 | ||
| WO-2025212750-A1 | Biomolecule preparation methods, kits, and systems | Pending | 03-Apr-2024 | ||
| US-20250224408-A1 | Biomarkers for diagnosing alzheimer's disease and related dementias | Pending | 05-Jan-2024 | ||
| US-20250207155-A1 | Particle-based bioseparation assays | Pending | 22-Dec-2023 | ||
| WO-2025137588-A1 | Particle-based bioseparation assays | Inactive | 22-Dec-2023 | C12P1/00 |
Seer Signals
Seer Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Seer ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.89 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Seer FAQs
-
When was Seer founded?
Seer was founded in 2017.
-
Where is Seer headquartered?
Seer is headquartered in Redwood City, CA.
-
What is the size of Seer?
Seer has 124 total employees.
-
What industry is Seer in?
Seer’s primary industry is Other Healthcare Technology Systems.
-
Is Seer a private or public company?
Seer is a Public company.
-
What is Seer’s stock symbol?
The ticker symbol for Seer is SEER.
-
What is the current stock price of Seer?
As of 19-Nov-2026 the stock price of Seer is $1.39.
-
What is the current market cap of Seer?
The current market capitalization of Seer is $82.9M.
-
What is Seer’s current revenue?
The trailing twelve month revenue for Seer is $13.6M.
-
Who are Seer’s competitors?
Nautilus Biotechnology, Quanterix, Agilent Technologies, Bio-Rad Laboratories, and Thermo Fisher Scientific are some of the 7 competitors of Seer.
-
What is Seer’s annual earnings per share (EPS)?
Seer’s EPS for 12 months was -$1.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process